WO2012150784A3 - 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 - Google Patents

신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2012150784A3
WO2012150784A3 PCT/KR2012/003308 KR2012003308W WO2012150784A3 WO 2012150784 A3 WO2012150784 A3 WO 2012150784A3 KR 2012003308 W KR2012003308 W KR 2012003308W WO 2012150784 A3 WO2012150784 A3 WO 2012150784A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabolic diseases
indole derivative
preventing
preparation
pharmaceutically acceptable
Prior art date
Application number
PCT/KR2012/003308
Other languages
English (en)
French (fr)
Other versions
WO2012150784A2 (ko
Inventor
이현선
김문옥
최용석
이경
박정준
서지희
정화영
조성찬
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2012150784A2 publication Critical patent/WO2012150784A2/ko
Publication of WO2012150784A3 publication Critical patent/WO2012150784A3/ko
Priority to US14/070,683 priority Critical patent/US8906952B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

본 발명은 인돌 유도체에 관한 것으로, 본 발명에 따른 상기 인돌 유도체는 지질대사 과정에서 비만, 당뇨병, 고지혈증, 동맥경화증, 지방간 등과 같은 대사성 질환을 유발하는 디아실글리세롤 아실트랜퍼라제(diacylglycerol acyltransferase; DGAT)의 활성을 효과적으로 억제하여 지질대사와 에너지대사를 효과적으로 조절하므로, 대사성 질환의 예방 또는 치료용 약학적 조성물로 유용하게 사용될 수 있다.
PCT/KR2012/003308 2011-05-03 2012-04-27 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 WO2012150784A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/070,683 US8906952B2 (en) 2011-05-03 2013-11-04 Indole derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic diseases containing same as active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0042124 2011-05-03
KR20110042124 2011-05-03
KR1020120044527A KR101392334B1 (ko) 2011-05-03 2012-04-27 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
KR10-2012-0044527 2012-04-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/070,683 Continuation-In-Part US8906952B2 (en) 2011-05-03 2013-11-04 Indole derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic diseases containing same as active ingredient

Publications (2)

Publication Number Publication Date
WO2012150784A2 WO2012150784A2 (ko) 2012-11-08
WO2012150784A3 true WO2012150784A3 (ko) 2013-01-03

Family

ID=47108113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003308 WO2012150784A2 (ko) 2011-05-03 2012-04-27 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물

Country Status (3)

Country Link
US (1) US8906952B2 (ko)
KR (1) KR101392334B1 (ko)
WO (1) WO2012150784A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104610156A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和腈基苯类gpr119激动剂、制备方法及其用途
RU2019117958A (ru) * 2016-11-18 2020-12-18 Мерк Шарп И Доум Корп. Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
KR100795462B1 (ko) * 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR100807718B1 (ko) * 2006-10-17 2008-02-28 한국생명공학연구원 인돌 유도체를 유효성분으로 함유하는 대사성 질환 예방 및치료용 약학적 조성물
KR20100070664A (ko) * 2008-12-18 2010-06-28 연세대학교 산학협력단 인돌-3-카비놀 유도체를 유효성분으로 포함하는 비만, 고지혈증, 지방간 또는 당뇨의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52139855A (en) 1976-05-17 1977-11-22 Omron Tateisi Electronics Co Long nut and its preparation
US5245046A (en) 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
BR9814913A (pt) 1998-02-16 2001-10-23 Kitasato Inst Nova substância kf-1040 e processo para produção da mesma
WO2000058491A1 (fr) 1999-03-25 2000-10-05 The Kitasato Institute Nouvelles substances kf-1040t4a, kf-1040t4b, kf-1040t5a et kf-1040t5b et leur procede de production
KR100460438B1 (ko) 2001-12-01 2004-12-08 한국생명공학연구원 아실 코에이:디아실글리세롤 아실트랜스퍼라제활성저해제인 신규 폴리아세틸렌계 화합물 및 이의 제조방법
KR100577320B1 (ko) 2002-10-23 2006-05-10 한국생명공학연구원 아실 코에이:디아실글리세롤 아실트랜스퍼라제 활성 저해제인 퀴놀론 알칼로이드 화합물을 유효성분으로 함유하는 중성지방 강하제
TW200606137A (en) 2004-07-02 2006-02-16 Sankyo Co Urea derivatives
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
DE602005025517D1 (de) 2004-10-15 2011-02-03 Bayer Healthcare Llc Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas
EP1881958B1 (en) 2005-05-10 2009-09-09 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EA018724B1 (ru) * 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
KR100795462B1 (ko) * 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR100807718B1 (ko) * 2006-10-17 2008-02-28 한국생명공학연구원 인돌 유도체를 유효성분으로 함유하는 대사성 질환 예방 및치료용 약학적 조성물
KR20100070664A (ko) * 2008-12-18 2010-06-28 연세대학교 산학협력단 인돌-3-카비놀 유도체를 유효성분으로 포함하는 비만, 고지혈증, 지방간 또는 당뇨의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
KR20120124357A (ko) 2012-11-13
WO2012150784A2 (ko) 2012-11-08
KR101392334B1 (ko) 2014-05-12
US20140057909A1 (en) 2014-02-27
US8906952B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
EP4338805A3 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
NZ597193A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2013064900A8 (en) Oral immediate release formulations for substituted quinazolinones
MY158504A (en) Fatty acid niacin conjugates and their uses
MY160249A (en) Fatty acid fumarate derivatives and their uses
NZ719360A (en) Preparation, uses and solid forms of obeticholic acid
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
IN2015DN00137A (ko)
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2012161518A3 (ko) ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물
WO2014006636A3 (en) Stable compositions of fesoterodine
WO2012134172A3 (ko) 오미자 에틸아세테이트 분획물 또는 이로부터 분리한 우웨이지수 ｃ를 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
EP2891496A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMPLEX EXTRACT OF AURANTII NOBILIS PERICARPIUM AND CRATAEGUS AS AN ACTIVE INGREDIENT IN THE TREATMENT OR PREVENTION OF OBESITY OR METABOLIC DISEASES OF LIPIDIC ORIGIN
WO2013100718A3 (ko) 라저스트로에미아 오바리폴리아 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 질환 또는 천식의 예방 또는 치료용 약학적 조성물
WO2012150784A3 (ko) 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
HK1223011A1 (zh) 大葉冬青提取物為有效成分的藥物組合物
WO2012144854A3 (ko) 리코찰콘 ａ의 신규 용도
WO2010135505A3 (en) Crystalline forms of 4-[6-(6-methanesulfonyl-2-methylpyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
WO2013162298A8 (ko) 신규한 베타 알라닌 유도체, 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2011139255A3 (en) Pharmaceutical compositions comprising cefetamet
WO2011149206A3 (en) Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same
WO2011010174A8 (en) Crystalline form i rosuvastatin zinc salt
WO2012066365A3 (en) Crystalline pharmaceutically active ingredients
GR1007734B (el) Φαρμακευτικο σκευασμα περιεχον ατορβαστατινη και μεθοδος για την παρασκευη αυτου
WO2011138762A3 (en) Cholesterol ester for reducing cholesterol absorption

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12779330

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12779330

Country of ref document: EP

Kind code of ref document: A2